BIORQ Stock — Biora Therapeutics, Inc.

Biora Therapeutics, Inc. (BIORQ)

Updated October 9, 2026.

BIORQ is a Stock. Its deepest 1-year drawdown was 100.0%.

Biora Therapeutics is a clinical-stage biotechnology company developing oral delivery platforms for biotherapeutics, including NaviCap for targeted gastrointestinal delivery in inflammatory bowel disease and BioJet for systemic oral delivery of large molecules. The company does not currently distribute to shareholders. As of May 2025, Biora Therapeutics is undergoing liquidation under Chapter 7 bankruptcy following a Chapter 11 filing in December 2024.

BIORQ performance

Returns are updating. BIORQ's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 100.0%.

BIORQ key facts

Asset type

Stock

Asset class

Equity

Inception date

06/19/2020

Distribution frequency

None

Last close

$0.0001 (stale; as of 2026-10-09)

Market cap

$452

Average volume

0.0

Payout ratio

0.0%

EPS

$-0.01

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BIORQ risks and drawbacks

The deepest 1-year drawdown on record here is 100.0%.

Who may consider BIORQ — and who may not

It is a weaker fit for investors who need monthly cash flow (BIORQ does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BIORQ

• All tickers starting with B

Frequently asked questions